Polio Resurfaces in Laos

Genetic sequencing of the virus suggests it has been circulating for two years in an area with low immunization rates

Join Our Community of Science Lovers!

By Reuters Staff

GENEVA/LONDON (Reuters) - Laos has suffered a case of vaccine-derived polio, the World Health Organization said on Monday, in a new setback to a global plan to eradicate the crippling disease after the virus resurfaced in Ukraine and Mali.

The WHO said an 8-year-old boy died of the disease on Sept. 11, and genetic sequencing suggested the virus strain has been circulating in the area of Bolikhamxay province, which has low immunization rates, for more than two years.

On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.

A global vaccination campaign has all but beaten the wild polio virus, with only Pakistan and Afghanistan reporting cases of wild polio virus infection this year.

Specialists have warned that vaccine-derived cases - such as this one in Laos and previous ones in Ukraine and Mali - could hamper progress towards global eradication.

The WHO stressed that "ending polio for good requires eliminating both wild and vaccine-derived polio".

It added, however, that because of relatively limited travel to and from this area, and because of extra immunization campaigns planned in response, the risk of international spread of this polio strain from Laos is low.

Laos has been free of the wild polio virus since 1993, but poor immunization rates mean people are at risk of infection with strains of the virus that can mutate in sewage after being excreted by immunized children.

The risk of vaccine-derived polio cases can be avoided by switching from using live oral polio vaccines (OPV) - which are highly effective, cheap, easy to deliver but contain live virus, - to "inactivated" vaccines (IPV), which are not effective for fighting endemic disease but contain no live virus.

The WHO said the use of OPV is being scaled down in a phased manner as countries eliminate circulating wild polio virus strains.

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American